Followers | 145 |
Posts | 27561 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, January 25, 2006 6:54:36 AM
25.1.06 | 12:07 By Sharon Shpurer
Most of the investment banks left their investment ratings for Aladdin Knowledge Systems (Nasdaq, TASE: ALDN) unchanged after the company published its fourth-quarter results. Nor did most change their price objectives for the data security company's stock.
CIBC didn't either: its recommendation remains Outperform and its 12-month price target is $21, which is roughly 20% above Aladdin's share price on Nasdaq.
The investment bank wrote that the upswing in the enterprise software security market brought Aladdin strong results in the last quarter of 2005. Altogether, CIBC continues to believe in the long-term story of Aladdin, the analysts say.
The analysts were undeterred by the weakness in Aladdin's core market of digital rights management (DRM) systems for enterprises. It's a hiccup, not a change, they say and remain bullish on the company's lead in that segment.
Aladdin stock from 2002
Meanwhile, Jefferies & Co were rather less impressed by Aladdin's fourth quarter. Its 12-month price target is $17 and the investment rating is Hold.
The investment bank decided to lower its 2006 forecasts from $95.9 million revenues to $94.1 million.
Jefferies & Co lowered its earnings projection from $1.14 to $1.12 per share, and cut its first-quarter 2006 sales forecast from $23 million to $22.7 million.
It is concerned about the significant slowdown in Aladdin's DRM operations. Given that, and the caution the management headed by Yanki Margalit evinced regarding its strategic collaboration with Cisco Vision, the analysts opted to be cautious about investment in the Israeli company.
Deutsche Bank shares Jefferies & Co's concerns and also elected for a Hold rating, though its 12-month price target is $18. One quarter does not a trend portend, the German bank says, but it does increase the risk factor regarding 2006.
http://www.haaretz.com/hasen/spages/674744.html
Dubi
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM